# A ring-fenced metastasis programme with metastasis-specific endpoints

Source: https://onco.cc/ideas/idea-fund-metastasis-moonshot/  
OnCo record `idea-fund-metastasis-moonshot` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Metastasis causes about nine in ten cancer deaths but gets a small slice of research money. This would ring-fence a tenth of national cancer research budgets for the biology and trials of spread itself.

## Summary

A dedicated, multi-year programme funds metastasis biology (dissemination, dormancy, organ-specific colonisation), metastasis-directed therapies and, crucially, trials whose primary endpoint is the prevention or delay of new metastases rather than shrinkage of existing ones. It would include model-building (autochthonous and humanised metastasis models), a metastatic tissue banking network with rapid autopsy, and a trial arm for 'anti-metastatic' agents tested in the adjuvant and molecular residual disease setting where they can plausibly work.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Ring-fencing 10% of a national cancer research budget for metastasis for a decade at least triples the number of registered interventional trials with a metastasis-prevention primary endpoint and produces at least one approved agent labelled for prevention of metastatic relapse.
- Rationale: Analyses of NCI portfolios have found metastasis-specific research at a few percent of spend despite its share of mortality; the Metastasis Research Society and the UK's Cancer Grand Challenges have argued that the field is starved of models and of trial designs that can show anti-metastatic effect. Ring-fencing worked to create fields in HIV cure research and in paediatric oncology through the Children's Oncology Group.
- Proposed test: Portfolio audit at baseline, then a funded pilot of 3 to 5 metastasis-prevention trials in high-risk resected disease (for example pancreatic, TNBC, melanoma) using ctDNA-defined populations; success is feasibility of accrual, endpoint acceptance by regulators, and a signal in at least one trial within six years.
- Maturity: speculative
- Actor: policy

## Sources

- Cancer Grand Challenges: https://cancergrandchallenges.org/

## Connected records

- ideas: [ctDNA-triggered escalation in early TNBC](https://onco.cc/ideas/idea-ctdna-escalation-tnbc/), [Ten-year awards for scientists who commit to one hard problem](https://onco.cc/ideas/idea-fund-ten-year-hard-problem-awards/), [Treat brain metastases as a disease with its own trials programme](https://onco.cc/ideas/idea-fund-brain-metastases-programme/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Patient-derived xenografts](https://onco.cc/technologies/pdx-models/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/)
- people: [Klaus Pantel](https://onco.cc/people/klaus-pantel/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-metastasis-moonshot.json